FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow – FDA.gov
OncLive |
FDA approves first treatment for rare disease in patients who receive stem cell transplant from blood or bone marrow
FDA.gov The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant … First Treatment Approved for Disease Linked to Stem Cell Transplant FDA Approves Defibrotide for Hepatic VOD Following Stem Cell Transplantation FDA Says “Yes” to Defibrotide (Defitelio) for Hepatic Veno-Occlusive Disease Following Stem–Cell Transplantation |
